Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S, Patel M, Huck J, Zhang M, Balani SK, Yang J, Chen S, Mettetal J, Manfredi M, Shyu WC, Ecsedy JA, Chakravarty A. Palani S, et al. Among authors: chakravarty a. Cancer Chemother Pharmacol. 2013 Dec;72(6):1255-64. doi: 10.1007/s00280-013-2305-8. Epub 2013 Oct 8. Cancer Chemother Pharmacol. 2013. PMID: 24101146
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Huck JJ, Zhang M, Mettetal J, Chakravarty A, Venkatakrishnan K, Zhou X, Kleinfield R, Hyer ML, Kannan K, Shinde V, Dorner A, Manfredi MG, Shyu WC, Ecsedy JA. Huck JJ, et al. Among authors: chakravarty a. Mol Cancer Ther. 2014 Sep;13(9):2170-83. doi: 10.1158/1535-7163.MCT-14-0027. Epub 2014 Jun 30. Mol Cancer Ther. 2014. PMID: 24980948
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
Chakravarty A, Shinde V, Tabernero J, Cervantes A, Cohen RB, Dees EC, Burris H, Infante JR, Macarulla T, Elez E, Andreu J, Rodriguez-Braun E, Rosello S, von Mehren M, Meropol NJ, Langer CJ, ONeil B, Bowman D, Zhang M, Danaee H, Faron-Yowe L, Gray G, Liu H, Pappas J, Silverman L, Simpson C, Stringer B, Tirrell S, Veiby OP, Venkatakrishnan K, Galvin K, Manfredi M, Ecsedy JA. Chakravarty A, et al. Cancer Res. 2011 Feb 1;71(3):675-85. doi: 10.1158/0008-5472.CAN-10-1030. Epub 2010 Dec 10. Cancer Res. 2011. PMID: 21148750 Clinical Trial.
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB. Manfredi MG, et al. Among authors: chakravarty a. Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20. Clin Cancer Res. 2011. PMID: 22016509
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ, Li Y, Chakravarty A, Lu C, Xia CQ, Chen S, Pusalkar S, Zhang M, Ecsedy J, Manfredi MG, Wu JT, Shyu WC, Balani SK. Yang JJ, et al. Among authors: chakravarty a. Drug Metab Lett. 2014 Jul;7(2):96-104. doi: 10.2174/1872312807666131229122359. Drug Metab Lett. 2014. PMID: 24484538
568 results